Since MYC amplification co-occurring with EGFR activation, is frequently observed in advanced HCC (http://www.cbioportal.org), we suggest that EGFR or MAPK status might be considered ahead of JQ1 therapy. This evidence concerns the gene MYC and hepatocellular carcinoma.